RenovoRx's Upcoming Participation at a Vital Health Forum
RenovoRx, Inc. (NASDAQ: RNXT), a pioneering life-sciences company, is poised to showcase its advancements at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum. This is set to be a significant opportunity for the company to share insights on its innovative targeted oncology therapies. The forum will be held on November 20, where CEO Shaun Bagai will take the stage to discuss pivotal developments within the company.
Highlighting Innovations and Market Demand
Mr. Bagai aims to shed light on the commercialization progress of RenovoRx, focusing on the urgent clinical needs that RenovoCath addresses. With a growing demand for targeted drug delivery solutions, he will share how RenovoCath is becoming a standout product among both new and existing customers. Its patented technology is designed to deliver medications directly to tumors, minimizing systemic exposure and enhancing treatment efficacy.
Updates on Clinical Trials
At the upcoming forum, attendees will gain insights into the ongoing Phase III TIGeR-PaC clinical trial. This trial evaluates the efficacy of RenovoRx's unique intra-arterial drug-device combination, combining gemcitabine and RenovoCath in treating locally advanced pancreatic cancer. Mr. Bagai will also discuss a new post-marketing observational registry study aimed at assessing long-term safety and survival outcomes for patients receiving treatment through RenovoCath.
Details on the Forum
Event: Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum
Date: November 20, 2025
Location: Westin NY Grand Central, New York
Connecting with RenovoRx
For investors interested in a more personalized dialogue, opportunity for one-on-one meetings with Mr. Bagai can be arranged through Canaccord Genuity representatives or via KCSA Strategic Communications.
About RenovoRx, Inc.
RenovoRx, Inc. is dedicated to developing innovative therapies that address significant oncological challenges. The company’s flagship product, RenovoCath, is an FDA-cleared local drug delivery device that targets unfulfilled medical needs in cancer treatment. With its Trans-Arterial Micro-Perfusion (TAMP™) platform, RenovoRx aims to deliver therapeutic agents closer to tumor sites, potentially reducing side effects and improving patient outcomes.
In addition to RenovoCath, the company is conducting the Phase III TIGeR-PaC trial, involving the IAG product candidate, which is poised to make significant contributions to oncology treatment protocols upon successful outcomes. With recent commercial orders for RenovoCath, including repeat purchases from several prominent cancer centers, RenovoRx is well-positioned to expand its market presence and enhance accessibility to its innovative therapies.
To learn more about RenovoRx and its offerings, visit their official website. Additionally, keep up with the latest updates on their social media platforms including Facebook, LinkedIn, and X.
Frequently Asked Questions
What is RenovoRx known for?
RenovoRx specializes in developing innovative targeted oncology therapies, significantly focusing on its patented RenovoCath device.
What will the forum focus on?
The forum will highlight RenovoRx’s commercialization progress, updates on clinical trials, and insights into market demands for targeted therapy solutions.
Where will the forum be held?
The Canaccord Genuity forum will take place at Westin NY Grand Central in New York.
How can investors connect with RenovoRx's CEO?
Investors can arrange one-on-one meetings with CEO Shaun Bagai through Canaccord Genuity representatives or KCSA Strategic Communications.
What is the significance of the Phase III clinical trial?
The Phase III clinical trial is critical as it evaluates the effectiveness of RenovoRx's innovative drug-device combination for treating pancreatic cancer.
